Martingale Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.24M Buy
260,311
+50,465
+24% +$678K 0.08% 240
2025
Q4
$2.64M Buy
209,846
+9,643
+5% +$110K 0.07% 259
2025
Q3
$2M Buy
200,203
+45,916
+30% +$412K 0.05% 317
2025
Q2
$1.25M Buy
154,287
+2
+0% +$15 0.03% 416
2025
Q1
$1.29M Buy
154,285
+4,637
+3% +$38.7K 0.03% 400
2024
Q4
$1.19M Buy
149,648
+53,944
+56% +$453K 0.03% 435
2024
Q3
$796K Buy
95,704
+21
+0% +$164 0.02% 522
2024
Q2
$608K Hold
95,683
0.01% 563
2024
Q1
$580K Buy
+95,683
New +$540K 0.01% 591

Other funds holding AMRX

Martingale Asset Management's AMRX Position: Q1 2026 in Review

Martingale Asset Management increased its Amneal Pharmaceuticals (AMRX) stake by 24% in Q1 2026, buying an estimated $678K and bringing the position to 260,311 shares worth $3.24M. The position accounts for 0.08% of the portfolio, ranked #240.

Martingale Asset Management first reported a position in AMRX in Q1 2024 and has held it in 9 quarters since. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Martingale Asset Management held 260,311 shares of Amneal Pharmaceuticals worth $3.24M as of Q1 2026.
  • Martingale Asset Management bought 50,465 Amneal Pharmaceuticals shares in Q1 2026, an estimated $678K.
  • Amneal Pharmaceuticals made up 0.08% of Martingale Asset Management's portfolio in Q1 2026, its #240 holding.
  • Martingale Asset Management first reported a position in Amneal Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.